Parkinson's disease

[Pharmacology & Therapeutics] Investigators summarize the latest studies on the role that altered neuronal autophagy plays in brain health and these pathological conditions, and how this knowledge can be leveraged for the development of novel therapeutics against them.

[RTL Luxembourg] The ISS will include an experiment by five students from the Luxembourg Center of System Biomedicine at Belval, who have been growing so-called "organoids", mini brains that will be able to grow in micro gravity and thus help advance research in the fight against Parkinson's disease.

[Molecular and Cellular Biochemistry] C57BL/6 mice were used to isolate and identify CD133+GFAP+CD117+Sca1+ cells in the hippocampal dentate gyrus region of the mouse brain as a novel neural stem cell population, in terms of cell phenotype, self-renewal capacity, and differentiation capability.

[Athira Pharma, Inc.] Athira Pharma, Inc. announced that patient dosing has begun in SHAPE, a Phase II clinical trial of ATH-1017 for the treatment of Parkinson's disease dementia and Dementia with Lewy bodies. ATH-1017 is a small molecule designed to enhance the activity of Hepatocyte Growth Factor and its receptor, MET, to impact neurodegeneration and regenerate brain tissue.

[Inhibikase Therapeutics, Inc.] Inhibikase Therapeutics, Inc. announced dosing of the first Parkinson's patient in its Phase Ib clinical trial of IkT-148009, an Abelson Tyrosine Kinase, or c-Abl, inhibitor for the treatment of Parkinson's disease.

[Movement Disorders] Investigators evaluated the difference between controls' and phosphatase and tensin homolog-induced putative kinase 1 (PINK1) patients' derived neurons in their transition from neuroepithelial stem cells to neurons, allowing them to identify potential pathways to target with repurposed compounds.